Literature DB >> 17875793

The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity.

Chien-Hsing Chang1, Edmund A Rossi, David M Goldenberg.   

Abstract

The idea, approach, and proof-of-concept of the dock and lock (DNL) method, which has the potential for making a large number of bioactive molecules with multivalency and multifunctionality, are reviewed. The key to the DNL method seems to be the judicious application of a pair of distinct protein domains that are involved in the natural association between protein kinase A (PKA; cyclic AMP-dependent protein kinase) and A-kinase anchoring proteins. In essence, the dimerization and docking domain found in the regulatory subunit of PKA and the anchoring domain of an interactive A-kinase anchoring protein are each attached to a biological entity, and the resulting derivatives, when combined, readily form a stably tethered complex of a defined composition that fully retains the functions of individual constituents. Initial validation of the DNL method was provided by the successful generation of several trivalent bispecific binding proteins, each consisting of two identical Fab fragments linked site-specifically to a different Fab. The integration of genetic engineering and conjugation chemistry achieved with the DNL method may not only enable the creation of novel human therapeutics but could also provide the promise and challenge for the construction of improved recombinant products over those currently commercialized, including cytokines, vaccines, and monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875793     DOI: 10.1158/1078-0432.CCR-07-1217

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

Authors:  Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

3.  Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo.

Authors:  Philippe Valadon; Bryan Darsow; Tim N Buss; Malgorzata Czarny; Noelle M Griffin; Han N Nguyen; Phil Oh; Per Borgstrom; Adrian Chrastina; Jan E Schnitzer
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

Review 4.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 5.  Whither Radioimmunotherapy: To Be or Not To Be?

Authors:  Damian J Green; Oliver W Press
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

6.  Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.

Authors:  Pankaj Gupta; David M Goldenberg; Edmund A Rossi; Chien-Hsing Chang
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

7.  Chemokine upregulation in response to anal sphincter and pudendal nerve injury: potential signals for stem cell homing.

Authors:  Levilester Salcedo; Nikolai Sopko; Hai-Hong Jiang; Margot Damaser; Marc Penn; Massarat Zutshi
Journal:  Int J Colorectal Dis       Date:  2011-06-25       Impact factor: 2.571

8.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

9.  Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.

Authors:  Soomin Yoon; Yun-Hee Kim; Se Hun Kang; Seok-Ki Kim; Hwa Kyoung Lee; Hyori Kim; Junho Chung; In-Hoo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-01       Impact factor: 4.553

10.  CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.

Authors:  Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; Rhona Stein; Chien-Hsing Chang
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.